Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Massimo Andreoni and Loredana Sarmati.
Connection Strength

2.292
  1. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. Mult Scler Relat Disord. 2021 Oct; 55:103157.
    View in: PubMed
    Score: 0.239
  2. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. Sci Rep. 2021 06 17; 11(1):12762.
    View in: PubMed
    Score: 0.238
  3. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. Mult Scler Relat Disord. 2020 Oct; 45:102442.
    View in: PubMed
    Score: 0.224
  4. An in-depth analysis of nosocomial bloodstream infections due to Gram-negative bacilli: clinical features, microbiological characteristics and predictors of mortality in a 1 year, prospective study in a large tertiary care Italian hospital. Infect Dis (Lond). 2019 Jan; 51(1):12-22.
    View in: PubMed
    Score: 0.200
  5. High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance. PLoS One. 2018; 13(3):e0195045.
    View in: PubMed
    Score: 0.190
  6. Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS One. 2017; 12(5):e0176881.
    View in: PubMed
    Score: 0.179
  7. Non-B HIV type 1 subtypes: replicative capacity and response to antiretroviral therapy. AIDS Res Hum Retroviruses. 2004 Aug; 20(8):816-8.
    View in: PubMed
    Score: 0.074
  8. Primary human herpesvirus 8 infection in immunocompetent children. JAMA. 2002 Mar 13; 287(10):1295-300.
    View in: PubMed
    Score: 0.063
  9. Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. Front Pharmacol. 2021; 12:666600.
    View in: PubMed
    Score: 0.059
  10. Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients. EBioMedicine. 2021 Apr; 66:103341.
    View in: PubMed
    Score: 0.059
  11. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa588.
    View in: PubMed
    Score: 0.057
  12. Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. Life (Basel). 2020 Nov 23; 10(11).
    View in: PubMed
    Score: 0.057
  13. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. J Affect Disord. 2021 01 01; 278:339-340.
    View in: PubMed
    Score: 0.056
  14. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020 08; 88:11-16.
    View in: PubMed
    Score: 0.055
  15. Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. BMC Public Health. 2019 May 28; 19(1):645.
    View in: PubMed
    Score: 0.052
  16. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J Viral Hepat. 2019 07; 26(7):846-855.
    View in: PubMed
    Score: 0.051
  17. Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study. BMC Infect Dis. 2018 Dec 19; 18(1):683.
    View in: PubMed
    Score: 0.050
  18. Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018 10; 41(4):247-255.
    View in: PubMed
    Score: 0.049
  19. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses. 2018 07 09; 10(7).
    View in: PubMed
    Score: 0.048
  20. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
    View in: PubMed
    Score: 0.048
  21. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 01; 72(12):3420-3424.
    View in: PubMed
    Score: 0.047
  22. Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. J Glob Antimicrob Resist. 2017 09; 10:106-112.
    View in: PubMed
    Score: 0.045
  23. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
    View in: PubMed
    Score: 0.045
  24. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 04; 37(4):514-528.
    View in: PubMed
    Score: 0.044
  25. Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy. J Antimicrob Chemother. 2017 01; 72(1):220-226.
    View in: PubMed
    Score: 0.043
  26. Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV. Eur J Epidemiol. 2004; 19(5):467-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.